An RXR-selective analog attenuates the RAR alpha-selective analog-induced differentiation and non-G(1)-restricted growth arrest of NB4 cells

被引:10
作者
Brooks, SC [1 ]
Sturgill, R [1 ]
Choi, J [1 ]
Yen, A [1 ]
机构
[1] CORNELL UNIV, COLL VET MED, DEPT PATHOL, CANC BIOL LAB, ITHACA, NY 14853 USA
关键词
D O I
10.1006/excr.1997.3620
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
NB4, a human acute promyelocytic leukemia cell line expressing the promyelocyte-retinoic acid receptor alpha (PML-RAR alpha) hybrid protein was treated with RAR- and retinoid X receptor (RXR)-selective analogs to determine their effects on cell proliferation, retinoblastoma (RE) tumor-suppressor protein phosphorylation, and differentiation. An RAR- or just RAR alpha-selective analog alone induced similar cell population growth arrest, cell cycle arrest without restriction to G(1), hypophosphorylation of RB, and myelomonocytic cell surface differentiation marker expression (CD11b). In addition, an RAR alpha antagonist could inhibit the effects of the RAR alpha agonist completely. The RAR alpha-selective analog-elicited response was attenuated by simultaneous addition of various RXR-selective analogs. In contrast, each of the RXR-selective analogs was unable to induce any of the cellular responses analyzed. The growth arrest of NB4 cells is not G(1)-restricted and occurs at all points in the cell cycle, Cells growth arrested by treatment with an RAR alpha-selective analog show primarily hypophosphorylated RE. When these cells are sorted into G(1) or S + G(2)/M subpopulations by flow cytometry, hypophosphorylated RE protein was in G(1) as well as S + G(2)/M cells. This suggests that the hypophosphorylated RE protein may be mediating the growth arrest of NB4 cells at all points in the cell cycle. These results are consistent with an involvement of PML-RAR alpha and/or RAR alpha in the transduction of the retinoid signal in NB4 cells. (C) 1997 Academic Press.
引用
收藏
页码:259 / 269
页数:11
相关论文
共 68 条
  • [1] THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT REPRESSES TRANSCRIPTION WHEN DIRECTLY BOUND TO THE PROMOTER
    ADNANE, J
    SHAO, ZH
    ROBBINS, PD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (15) : 8837 - 8843
  • [2] CHARACTERIZATION OF NUCLEAR RETINOIC ACID-BINDING ACTIVITY IN SENSITIVE LEUKEMIC-CELL LINES - CELL-SPECIFIC UPTAKE OF ATRA AND RAR-ALPHA PROTEIN MODULATION
    AGADIR, A
    CORNIC, M
    JEROME, M
    MENOT, ML
    CAMBIER, N
    GAUB, MP
    GOURMEL, B
    LEFEBVRE, P
    DEGOS, L
    CHOMIENNE, C
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 213 (01) : 112 - 122
  • [3] AHN MJ, 1995, ONCOGENE, V10, P2307
  • [4] Alcalay Myriam, 1995, Blood, V86, p164A
  • [5] A RETINOIC ACID RECEPTOR-ALPHA ANTAGONIST SELECTIVELY COUNTERACTS RETINOIC ACID EFFECTS
    APFEL, C
    BAUER, F
    CRETTAZ, M
    FORNI, L
    KAMBER, M
    KAUFMANN, F
    LEMOTTE, P
    PIRSON, W
    KLAUS, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (15) : 7129 - 7133
  • [6] Ballerini Paola, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P521
  • [7] Benedetti L, 1996, BLOOD, V87, P1939
  • [8] SYNTHESIS OF HIGH SPECIFIC ACTIVITY [H-3] 9-CIS-RETINOIC ACID AND ITS APPLICATION FOR IDENTIFYING RETINOIDS WITH UNUSUAL BINDING-PROPERTIES
    BOEHM, MF
    MCCLURG, MR
    PATHIRANA, C
    MANGELSDORF, D
    WHITE, SK
    HEBERT, J
    WINN, D
    GOLDMAN, ME
    HEYMAN, RA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (03) : 408 - 414
  • [9] IDENTIFICATION OF A 2ND HUMAN RETINOIC ACID RECEPTOR
    BRAND, N
    PETKOVICH, M
    KRUST, A
    CHAMBON, P
    DETHE, H
    MARCHIO, A
    TIOLLAIS, P
    DEJEAN, A
    [J]. NATURE, 1988, 332 (6167) : 850 - 853
  • [10] INDUCTION OF DIFFERENTIATION OF THE HUMAN PROMYELOCYTIC LEUKEMIA-CELL LINE (HL-60) BY RETINOIC ACID
    BREITMAN, TR
    SELONICK, SE
    COLLINS, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (05): : 2936 - 2940